Daniel Ness

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity

Lutz Müller, Robert J. Mauthe, Christopher M. Riley et al. · Regulatory Toxicology and Pharmacology · 2006 · 454 citations

Biochemistry, Drug Resistance, Medicine +10

Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β

Margaret M. Racke, Laura Boone, Deena L. Hepburn et al. · Journal of Neuroscience · 2005 · 328 citations · Full text

Amyloid β, Passive Immunization, Immunology +17

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein et al. · JAMA Neurology · 2018 · 283 citations · Full text

First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers

Dale B. Schenk, Martin Koller, Daniel Ness et al. · Movement Disorders · 2016 · 242 citations · Full text

Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers

Eric Siemers, Michael Skinner, Robert A. Dean et al. · Clinical Neuropharmacology · 2005 · 214 citations